17:16:09 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Helus Pharma Inc
Symbol HELP
Shares Issued 57,364,294
Close 2026-11-16 C$ 10.94
Market Cap C$ 627,565,376
Recent Sedar+ Documents

Helus Pharma releases Approach study results

2026-11-16 17:00 ET - News Release

Mr. Michael Halstead reports

HELUS PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 APPROACH STUDY EVALUATING HLP003 AS ADJUNCTIVE TREATMENT IN MAJOR DEPRESSIVE DISORDER

Helus Pharma Inc. has released positive top-line results from Approach, its phase 3 pivotal study evaluating HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (MDD).

HLP003 achieved statistically significant and clinically meaningful results in the primary, key secondary and other secondary end points starting as early as day 2, and these were maintained at all time points.

At the primary end point of six 6 weeks, the least squares (LS) mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo (LS mean difference equals minus 7.6 points, p less than 0.0001, effect size equals 0.653).

The rapid onset of action with HLP003 was demonstrated with statistically significant LS mean MADRS reductions as early as day 2 of 16.1 points versus 11.0 points for placebo (LS mean difference equals minus 5.0 points, p equals 0.0013, effect size equals 0.438). This effect was durable with an LS mean reduction from baseline in the MADRS total score for HLP003 of 16.9 points versus 9.9 points for placebo (LS mean difference equals minus 7.0 points, p less than 0.0001, effect size equals 0.581) at the key secondary endpoint of 12 weeks.

"The large unmet need for patients with major depressive disorder who continue to experience persistent symptoms underscores the importance of new rapid-acting and well-tolerated adjunctive treatment options," said Michael Halstead, chief executive officer of Helus Pharma. "We believe these data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients and strengthen our momentum as we continue to progress HLP003 toward regulatory approval and potential commercialization."

Other efficacy results

HLP003 demonstrated statistically significant and clinically meaningful improvements in response and remission rates as an adjunctive therapy, starting as early as day 2 and maintained at all time points.

Additionally, HLP003 demonstrated statistically significant improvements on the Clinical Global Impression Scale compared with placebo starting as early as day 2 and maintained at all time points.

"The results from the Approach study set a new benchmark for what may be achievable with adjunctive treatment in major depressive disorder," said Roger S. McIntyre, MD, FRCPC, professor of psychiatry and pharmacology, University of Toronto. "The magnitude of benefit observed in this study is highly compelling and has the potential to redefine expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant."

Approximately two-thirds of patients with depression do not achieve remission with first-line antidepressant treatment (1). For patients who experience an inadequate response, adjunctive therapy is a commonly used treatment strategy. By adding a therapy to an existing antidepressant regimen, clinicians may be able to enhance treatment response while avoiding the need for antidepressant discontinuation, medication washout periods or the potential withdrawal symptoms associated with switching treatments.

Safety and tolerability

HLP003 was generally well tolerated in the Approach study. Most adverse events were mild to moderate in severity, transient and primarily limited to the day of dosing. There were three HLP003 treatment-related serious adverse events in the study. No new safety signals were identified.

About Approach and the Paradigm phase 3 program

Approach is a phase 3, multicentre, randomized, parallel-group, double-blind, placebo-controlled trial of adjunctive treatment with HLP003 of adult participants with MDD. The phase 3 study evaluated the efficacy and safety of HLP003 compared with placebo. The intent-to-treat population consisted of 222 participants with a DSM-5 confirmed diagnosis of MDD of moderate to severe degree as indicated by a MADRS total score of at least 24 at screening and baseline.

The baseline MADRS total scores of 32.7 for HLP003 and 33.8 for the placebo, reflected participants with moderate to severe depression. Participants continued taking their stable dose of antidepressant medication throughout the study.

Approach is the first of the three studies in the Paradigm phase 3 program that also includes Embrace, the second pivotal study that is currently continuing, and the Extend study. The company expects to report top-line results from the Embrace trial in Q4 (fourth quarter) 2027 (2) (3).

Extend is the continuing long-term extension study that will provide additional data on long-term safety, durability of effect and the potential role of redosing. Participants from Approach and Embrace may roll into Extend.

Conference call and webcast

Helus Pharma will host a conference call and webcast today at 8 a.m. ET to discuss results. To access the webcast, please visit the events and presentation page of Helus Pharma's website. The archived webcast will be available on the company's website on the events and presentations page following the presentation.

About Helus Pharma Inc.

Helus Pharma is a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the potential adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

(1) H.E. Pigott et al., BMJ Open. 2023; 13(7): e063095.

(2) There is no assurance that this timeline will be met or that the program will advance clinical trials, at all. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development and recruitment of patients for participation in clinical trials are dependent on various factors and are based on reasonable assumptions informed by current knowledge and information available to the company. Such statements are informed by, among other things, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, the number, availability, location and accessibility of clinical trial sites, regulatory guidelines for developing a drug with safety studies, proof-of-concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples and the company's development efforts to date.

(3) Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the company.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.